Vildagliptin-Associated Bullous Pemphigoid: A Case Report

نویسندگان
Roy, Debanjan ID 1
Gayen, Gunjan ID 2
Ghosh, Sandip ID 3
Aich, Shritama ID 4
Ara Begum, Sabnam ID 5
Talukder, Sucheto ID 6
Sarkar, Arisha ID 7

1 Post-Graduate Trainee, Department of Pharmacology, R. G. Kar Medical College and Hospital, Kolkata, India.

2 Post-Graduate Trainee, Department of Pharmacology, R. G. Kar Medical College and Hospital, Kolkata, India.

3 Principal, R.G. Kar Medical College and Hospital, Kolkata, India.

4 Multidisciplinary Research Unit, R.G. Kar Medical College and Hospital, Kolkata, India.

5 Associate Professor, Department of Pharmacology, R. G. Kar Medical College and Hospital, Kolkata, India.

6 Undergraduate Student (M.B.B.S), R.G. Kar Medical College and Hospital, Kolkata, India.

7 Undergraduate Student (M.B.B.S), R.G. Kar Medical College and Hospital, Kolkata, India.

doi
10.18502/ijdo.v16i2.15711
چکیده

 Objective: Bullous pemphigoid is a rare autoimmune skin disorder characterized by blistering, urticarial lesions, which are sometimes associated with adverse drug reactions. Vildagliptin is an oral anti-diabetic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. Materials and Methods: A 75-year-old female with a known case of type 2 Diabetes Mellitus, hypertension, and hypothyroidism ...

کلیدواژه‌ها
Antibody engineering, Anti-VEGF-A, Bioinformatic, Binding affinity, Ranibizumab